Impaired voltage-gated K+ channel expression in brain during experimental cancer cachexia  by Coma, Mireia et al.
Impaired voltage-gated Kþ channel expression in brain during
experimental cancer cachexia
Mireia Comaa;1, Rube¤n Vicentea;1, Silvia Busquetsa, Neus Carbo¤a, Michael M. Tamkunb,
Francisco J. Lo¤pez-Sorianoa, Josep M. Argile¤sa, Antonio Felipea;
aMolecular Physiology Laboratory, Departament de Bioqu|¤mica i Biologia Molecular, Universitat de Barcelona, Avda. Diagonal 645,
E-08028 Barcelona, Spain
bDepartment of Physiology and Pharmacology, Colorado State University, Fort Collins, CO, USA
Received 19 December 2002; accepted 23 December 2002
First published online 15 January 2003
Edited by Jesus Avila
Abstract Cancer-induced cachexia a¡ects most advanced can-
cer patients. It is characterized by anorexia, profound metabolic
dysfunctions, and severe neurological disorders. Here we show
that voltage-gated potassium channel (Kv) expression is im-
paired in the brain of tumor-bearing animals. Expression of
both delayed recti¢er (Kv1.1, Kv1.2, Kv1.3, Kv1.5, Kv1.6,
Kv2.1, Kv3.1, Kv4.2) and A-type potassium channels (Kv1.4,
Kv3.3, Kv3.4) was greatly down-regulated in brain from animals
bearing a Yoshida AH-130 ascites hepatoma. The possible com-
pensatory mechanisms (Kv1.4/Kv4.2), expression of redundant
genes (Kv3.1/Kv3.3) and heteromultimeric channel formation
(Kv2.1/Kv9.3) were also a¡ected. The high circulating levels
of TNFK and the reduced expression of the anti-apoptotic pro-
tein Bcl-XL found in the brain of tumor-bearing animals indi-
cate that this response could be mediated by an increase in brain
cell death due to apoptosis. The results suggest that brain func-
tion is impaired during cancer cachexia, and may account for
the cancer-induced anorectic response and other neurological
alterations.
5 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Cancer-induced cachexia is related to the presence and
growth of a tumor and leads to malnutrition due to the in-
duction of anorexia or decreased food intake. The cachexia-
anorexia syndrome is invariably associated with chronic
pathophysiological processes such as cancer progression and
HIV infection and is also the cause of mortality in more than
two thirds of patients with advanced cancer [1]. The condition
is characterized by a profound wasting of adipose tissue and
muscle, pain, depression, anxiety, taste and food aversions,
and several other homeostatic perturbations [2]. Cancer pro-
gression is multifactorial and chemically complex, and in-
volves cell-to-cell interactions induced by factors generated
by the tumor and/or the host. In this pathophysiological con-
text, cytokines act as autocrine, paracrine and intracrine ef-
fectors and induce important physiological changes. Cyto-
kines such as tumor necrosis factor K (TNFK), interleukin-1
(IL-1) and interleukin-6 (IL-6) induce most of the symptoms
and biochemical features of cancer cachexia and lead to neu-
rotoxicity and neurodegeneration [3,4]. In fact, abnormal lev-
els of cytokines have been described in brain after prostate
adenocarcinoma tumor progression [5]. Tumor implantation
activates the cytokine production network within the brain
and paracrine and autocrine interactions can sustain local
cytokine production through positive-feedback systems [6].
In this situation the neuronal processes can be modulated as
a result of direct ion channel regulation.
The electrical properties of nerve cells are determined
mostly by the voltage-gated potassium channels (Kv). Kv
play an essential role in regulating resting membrane poten-
tial, action potential duration and frequency, and neurotrans-
mitter release in mammalian neurons. The Kv family is the
most diverse and numerous group of channels including con-
ducting and non-conducting subunits. The complexity of the
functional protein may be further increased by the presence of
associations between gene products. Studies in heterologous
expression systems have highlighted the wide variety of bio-
physically and pharmacologically distinct Kv channels [7] car-
rying out diverse functions in neuronal physiology as key
determinants of membrane excitability. Indeed, the di¡erential
expression of Kv channel subunits in the brain may be crucial
to achieving the required neural response.
Though cancer-induced cachexia syndrome is invariably as-
sociated with abnormal behavior ^ anorexia ^ and neurolog-
ical disorders [2,8,9], the e¡ects of cancer-induced cachexia on
Kv channel expression in the brain have not been assessed.
The aim of the present study was to analyze the expression of
representative members of various conducting Kv channel
subfamilies (Kv1^4) and the non-conducting Kv9.3 modula-
tory subunit in brain from tumor-bearing animals. We show
that Kv gene expression is impaired in brain from animals
bearing a cachectic tumor. These results indicate that the nu-
merous neuronal dysfunctions observed during cancer-in-
duced cachexia may be due to changes in Kv channel expres-
sion, probably related to the induction of apoptosis in the
brain cell.
2. Materials and methods
2.1. Animals and tumor implantation
Female Wistar rats (approx. 200 g) from I¡a-Credo (France) were
fed ad libitum on a regular chow diet with free access to drinking
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water. A Yoshida AH-130 ascites hepatoma cell suspension (approx.
108 cells in 2 ml) was injected intraperitoneally, the control rats being
injected with 2 ml of 0.9% (w/v) NaCl solution as previously described
[10]. The Yoshida AH-130 is a rapidly growing tumor with a volume
doubling time of 1 day. Total cell content was estimated using trypan
blue staining. All extractions took place 7 days after tumor trans-
plantation [10].
2.2. Samples and TNFK measurements
Blood was collected from killed animals, and the plasma was ob-
tained by centrifugation and quickly frozen. Tissues were removed
and weighed. The brain was immediately frozen with liquid nitrogen
and maintained at 380‡C until use. All animal handling was ap-
proved by the ethics committee of the University of Barcelona.
Plasma TNF was measured by using an enzyme-linked immuno-
sorbent assay test (Genzyme Corp., Cambridge, MA, USA) following
the manufacturer’s instructions.
2.3. RNA extraction and Northern blot analysis
Total RNA from brain was isolated using the Tripure isolation
reagent (Roche Diagnostics, Mannheim, Germany). Up to 20 Wg of
total RNA was size-fractionated through 1% agarose, 3% formalde-
hyde gels in 20 mM 3-[N-morpholino]-propane sulfonic acid and
1 mM EDTA, pH 7.4. Application of equal amounts of RNA to
each lane was con¢rmed by the addition of ethidium bromide to the
samples before electrophoresis. The gel treatment and the high strin-
gency hybridization conditions are described elsewhere [11]. Filters
were hybridized overnight with 106 cpm/ml of the selected cDNA
probe and washed once for 30 min at 65‡C with 3USSC and 1%
SDS, once with 1USSC and 1% SDS, and once with 0.2USSC and
1% SDS before autoradiography. RNA from at least four indepen-
dent animals was analyzed for each group and a representative North-
ern blot is shown. All ¢lters were further hybridized to the 18S ribo-
somal band, and values were subtracted from the background,
corrected, and standardized. The densitometric analysis of the blots
was performed by using the Phoretix software (Nonlinear Dynamics,
Newcastle upon Tyne, UK). Results are the meansPS.E.M. of each
experimental group. Where indicated, statistical analysis by Student’s
t-test was performed.
2.4. cDNA probes, constructs and reverse transcription-polymerase
chain reaction (RT-PCR)
The use of Kv1.1, Kv1.2, Kv1.4, Kv2.1, Kv4.2 and Kv9.3 cDNA
probes has been documented before [12,13]. The murine Kv1.3 (741^
1459 bp, accession number: M30441), Kv1.5 (3003^3337 bp, accession
number: AF302768), Kv1.6 (1^3219 bp, accession number:
NM013568) and the rat 18S (494^706 bp, accession number:
M11188) cDNA probes were PCR generated in our laboratory from
brain (Kv1.3 and 18S) and heart (Kv1.5 and Kv1.6) total RNA using
selected primers. The PCR fragments were cleaned up by means of a
GFX PCR DNA and gel puri¢cation kit (Amersham Pharmacia Bio-
tech, Piscataway, WI, USA) and subcloned into the cloning site of the
pSTBlue-1 vector using the pSTBlue-1 acceptor vector kit (Novagen,
Madison, WI, USA) following the manufacturer’s instructions. The
Kv3.3 and Kv3.4 constructs were kindly provided by Dr. A. Castel-
lano and Dr. J. Lo¤pez-Barneo (University of Seville, Spain). The Bcl-
XL and Bax cDNAs were generated by PCR in our laboratory (ac-
cession numbers: U34963 and U49729, respectively).
In accordance with the mRNA expression of Kv1.5 and Kv3.1 in
brain [14,15], our Northern blot analysis gave a very low signal (not
shown). We therefore analyzed their relative mRNA expression by
semiquantitative RT-PCR. One Wg of total RNA from brain was
used on the Ready to go RT-PCR beads (Amersham Pharmacia Bio-
tech) for a semiquantitative analysis as previously described [16]. The
oligonucleotides selected to generate PCR products were: Kv1.5 (ac-
cession number: AF302768): F, 5P-GGATCACTCCATCACCAG-3P,
bp 3003^3020; R, 5P-GGCTTCCTCCTCTTCCTTG-3P, bp 3337^
3320; and Kv3.1 (accession number: Y07521): F, 5P-CTTCTTCATC
CTGGTCTCCATCAC-3P, bp 727^750; R, 5P-GTAGTAGAT-
GGTGGCAAAGAT-3P, bp 1231^1208. The RT reactions were incu-
bated at 94‡C for 5 min to inactivate the reverse transcriptase. The
PCR conditions were 0.5 min, 92‡C; 1 min, 58‡C; 2 min, 72‡C for 30
cycles. Ten Wl from the ¢nal RT-PCR reactions were electrophoresed
in a 1% agarose TBE gel (40 mM Tris, 20 mM acetic acid, 1 mM
EDTA, pH 8.0). The speci¢c amplicons in the exponential phase were
quanti¢ed by means of the Phoretix software. The r18S rRNA was
used as an internal control; 100 ng of total RNA from brain was used
in the RT-PCR reactions as described previously [16].
3. Results and discussion
Cancer-induced cachexia is associated with loss of body
mass together with adipose and muscle tissue wasting (Table
1). In tumor-bearing animals the brain is also a¡ected. Freitas
et al. [17] reported a substantial induction of oxidative stress
in rat brain during tumor burden. This may explain the asso-
ciation of human cancer cachexia with a variety of unde¢ned
neurological disorders [2^4].
Numerous central nervous system dysfunctions are related
with abnormal ion channel expression [18]. Previous studies
have shown a relation between anorexia and alterations in
potassium channels [19,20]. Voltage-dependent potassium
channels are a complex family of proteins engendered by
many members. Functional Kv channels are formed by either
a homo- or a heteromeric structure [7]. So, the variety of
currents generated could be the result of several Kv subunit
associations forming the pore structure, and the complexity of
the ion current could be further enhanced by the presence of
auxiliary beta subunits [21]. In terms of activity, Kv channels
can be divided into delayed recti¢ers, with slow or non-inac-
tivating current, and A-type channels, with a rapidly activat-
ing and rapidly inactivating current. Each type has a speci¢c
role in the membrane potential duration and propagation in
nerve and muscle.
We analyzed the mRNA expression for various conducting
and non-conducting Kv channel isoforms in brain during can-
cer-cachexia syndrome in rats. Fig. 1 shows the expression of
the Shaker family (Kv1). All members, not only delayed rec-
ti¢er channels Kv1.1, Kv1.2, Kv1.3 and Kv1.6 but also
A-type channels such as Kv1.4, showed a decrease in
mRNA expression (Fig. 1A), ranging from 30 to 60%
(Table 2). Kv1.5 has been described as a classical striated
muscle channel [22] and its expression in brain is very low
[14], but it can be detected by PCR in nerve [23]. Our RT-
PCR results showed that Kv1.5 mRNA expression also fell in
brains of tumor-bearing animals, by about 42% (Fig. 1B, Ta-
ble 2).
The Shab family (Kv2) is represented by Kv2.1 and Kv2.2.
Table 1
Body and tissue weights
Control Tumor
Body mass parameters (g)
Initial body weight 128P 9 134P 8
Final body weight 190P 10 205P 15
Tumor weight ^ 67P 8
Body weight gain 62 4
Tissues (g/100 initial body weight)
Skeletal muscle 0.69P 0.05 0.47P 0.03**
Heart 0.54P 0.03 0.36P 0.04*
WAT 0.45P 0.03 0.21P 0.03**
Brain 0.98P 0.08 0.74P 0.05*
Animals bearing Yoshida AH-130 ascites hepatoma were killed after
7 days, tissues were extracted and body and tissue mass were mea-
sured. Eight animals weighing 131P 8 g were homogeneously dis-
tributed before tumor inoculation. Skeletal muscle: gastrocnemius;
WAT: perirenal white adipose tissue. The results are mean-
s P S.E.M. of four animals. *P6 0.05; **P6 0.01 vs control Stu-
dent’s t-test.
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The Kv2.1 channel, which was ¢rst cloned from brain, is ex-
pressed in all mammalian brain neurons and it accounts for
the major component of delayed recti¢er current in nerve [24].
In addition, Kv2.1 has been identi¢ed as a major Kv channel
in the heart, and it also forms an oxygen-sensitive Kv channel
in vascular musculature [25]. Our results showed that Kv2.1
expression is decreased (V40%) in brain of animals under
cancer-cachexia syndrome (Fig. 2, Table 2). By overexpression
of a dominant-negative Kv2 subunit in embryonic neurons,
the Ikv is partially suppressed and action potentials are greatly
prolonged, supporting the idea major role in brain physiology
[26]. Thus, an impaired Kv2.1 expression could contribute to
some neural malfunctions during cachexia.
The A-type Kþ current is mostly conducted in the brain by
Kv1.4, Kv3.3, Kv3.4, Kv4.1, Kv4.2 and Kv4.3 [27]. As de-
scribed above, Kv1.4 mRNA expression is lower in tumor-
bearing animals. Several examples of compensatory behaviors
in members that engender similar currents have been de-
Fig. 1. RNA expression of Kv1 family members in the brain from animals under experimental cancer cachexia. At least four animals were in-
oculated with the Yoshida AH-130 ascites hepatoma cell suspension as described in the materials and methods section and total RNA was ana-
lyzed for Kv1 expression after 7 days of tumor growth. A: Kv1 Northern blot results. Values are meansPS.E.M. once corrected with the 18S
rRNA expression. B: Kv1.5 RT-PCR results. Representative amplicon results from the Kv1.5 and 18S RT-PCR reactions in exponential phase
are shown. C: control animals, T: tumor-bearing animals. *P6 0.05; **P6 0.01 vs C.
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scribed, such as an isoform switching between Kv4.2 and
Kv1.4 in rat ventricles from diabetic and myocardial infarc-
tion animals [28]. We did not ¢nd these compensatory mech-
anisms in brains from animals under cancer cachexia, since
Kv4.2 expression was also diminished (Fig. 2). This result
suggested major di¡erences between the pathological situa-
tions studied, since only cancer cachexia patients display neu-
rological disorders [2,9]. The Kv3 family (Shaw) also has sev-
eral delayed recti¢er (Kv3.1 and Kv3.2) and A-type channels
(Kv3.3 and Kv3.4) distributed throughout the central nervous
system [15]. The activation voltage and fast deactivation rates
generated by Kv3 proteins help repolarize action potentials
rapidly without a¡ecting the threshold for action potential
generation [15]. The Kv3 family may form functional channels
by heterotetrameric constructions, and experimental evidence
shows that they play critical roles in the generation of fast-
Table 2
Summary of the altered voltage-dependent Kþ channel expression in
brains from tumor-bearing rats
Channel Percentage of inhibition Channel Percentage of inhibition
Kv1.1 32P 2 Kv2.1 37P 5
Kv1.2 54P 10 Kv3.1 68P 7
Kv1.3 37P 5 Kv3.3 57P 8
Kv1.4 57P 8 Kv3.4 52P 10
Kv1.5 42P 6 Kv4.2 35P 3
Kv1.6 36P 6 Kv9.3 34P 3
Results are meansPS.E.M. of at least three di¡erent animals. The
percentage of inhibition is derived from Figs. 1 to 3. Values were
normalized to 18S ribosomal band levels expressed as arbitrary
units.
Fig. 2. Kv2, Kv3 and Kv4 family members in the brain from animals under experimental cancer cachexia. Legend is similar to Fig. 1. A: Kv
Northern blot results. Values are meansPS.E.M. once corrected with the 18S rRNA expression. B: Kv3.1 RT-PCR results. Representative am-
plicon results from the Kv3.1 and 18S RT-PCR reactions in exponential phase are shown. C, control animals; T, tumor-bearing animals.
*P6 0.05; **P6 0.01 vs C.
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spiking properties in cortical GABAergic interneurons [15].
Our results showed that mRNA expression of both A-types
Kv3.3 and Kv3.4 and the slowly inactivating Kv3.1 is lower in
brains from tumor-bearing animals (57% and 52% for the two
A-types and 68% for the delayed recti¢er, Fig. 2, Table 2). So,
although Kv3 channels may form a number of heteromeric
and compensatory structures to maintain a fast deactivating
current that generates rapid recovery after hyperpolarization
[15], this activity seems to be deteriorated in brains from ca-
chectic animals. In this context, certain compensatory mech-
anisms have been described and the expression of Kv3.1 and
Kv3.3 seems to be redundant, since single de¢cient mice did
not show any abnormal behavior. In contrast, double Kv3.1/
Kv3.3 mutants display severe ataxia, tremulous movements,
myoclonus, and hypersensitivity to ethanol [29].
Functional Kv channels may be formed by conducting and
non-conducting subunits that modify the overall ion current
kinetics [7]. Among non-conducting families, the Kv9 proteins
are associated to Kv2 conducting members, and Kv2.1 is re-
sponsible for a major current in the central nervous system
[24]. Kv2.1 and Kv9.3 channels have been implicated in oxy-
gen sensitivity [13,25]. However, the Kv2.1 channel alone can-
not account for the native O2-sensitive Kþ current, since the
heterologous expression of this protein is not activated in the
voltage range of the membrane potential. Co-expression of
Kv2.1/Kv9.3 generates currents activated at physiologically
relevant potentials and the Kþ currents are inhibited by hyp-
oxia [25]. We show that Kv9.3 mRNA expression is also de-
creased during cancer cachexia in brain (Fig. 3), as was the
case for Kv2.1 (Fig. 2). These results suggest that the possible
generation of heterotetrameric structures by these two genes
may be greatly handicapped. The potential role of the Kv2.1/
Kv9.3 channel in brain is not known, and further study is
required to elucidate this point.
Kv channels have a dynamic regulation attributed to the
relatively short half-lives of Kv mRNA and protein. Thus, we
analyzed the abundance of several Kv proteins by Western
blot (Kv1.3, Kv1.5 and Kv2.1) and found no relevant signal
in brain from tumor-bearing animals (not shown). However,
since in long-term conditions the Kv gene expression always
parallels the protein expression [28,30,31] and since the ca-
chectic syndrome is associated with an increased proteolytic
metabolism [1] the timing of the protein expression impair-
ment in the present study would be in agreement with pre-
vious observations.
Experimental cancer-induced cachexia is characterized by
an increase in pro-in£ammatory cytokines such as TNFK
and IL-1L. In the tumor-bearing animals, plasma TNFK con-
centration was increased (10P 4 and 307P 16 pg/ml for con-
trols and cachectic animals, respectively) as described else-
where [10]. In addition, the IL-1L mRNA was up-regulated
in brain from animals bearing prostate adenocarcinoma [6].
Both cytokines are clearly pro-apoptotic and this induction
may lead to neuronal death by apoptosis. To investigate this
hypothesis further, we analyzed the mRNA expression of sev-
eral anti- or pro-apoptotic proteins in brain. Bcl-2 family
proteins are divided functionally into death-inhibiting or
death-inducing members. Bcl-XL is known to enhance cell
survival, whereas Bax is pro-apoptotic [32,33]. Fig. 4 shows
that the mRNA levels of Bcl-XL are about 60% lower in the
brain of tumor-bearing animals. In contrast, the expression of
Bax was unaltered. This unsurprising result agrees with pre-
vious studies showing that the levels of Bax may remain stable
when apoptosis is mediated by TNFK [34]. Changes in brain
levels of these two proteins, especially Bcl-XL, have been as-
sociated with either neuronal death or protection in a number
of neurological disorders [32,33]. Previous investigations dem-
onstrate an increase in cytokine expression ^ TNFK, in par-
ticular ^ in the brain of patients with a range of tumoral
pathologies [35,36]. In addition, an increased brain TNFK
expression has been observed in rats bearing the cachectic
Walker 256 carcinoma (R. Curi, personal communication).
Our data also suggest that the levels of TNFK, and possibly
IL-1L [6], could be responsible for the massive neuronal death
by apoptosis. This result is clearly in agreement with the loss
of brain weight observed (Table 1). In this context, the down-
regulation of Kv channels may be related with a neuronal
dysfunction generated by cell brain apoptosis.
This study shows that Kv channel expression is impaired in
brain from tumor-bearing animals under cancer cachexia. The
possibility of homo- or heterotetrameric structures appears to
be severely a¡ected. We also show that possible compensatory
mechanisms are blocked in our model. To what extent our
results indicate a relationship between the neurological dys-
functions observed in cachectic patients and ion current dis-
orders is not known, but clearly a lower Kv expression may
modify not only overall brain activity but cognitive and be-
havioral responses as well. It is tempting to speculate that the
Fig. 3. Kv9.3 mRNA expression in the brain from animals under
experimental cancer cachexia. Legend is similar to Fig. 1. Values
are meansPS.E.M. once corrected with the 18S rRNA expression.
C, control animals; T, tumor-bearing animals. *P6 0.05 vs C.
Fig. 4. Pro-apoptotic Bax and anti-apoptotic Bcl-XL mRNA expres-
sion in brain from animals under experimental cancer cachexia. At
least four animals were analyzed and the result from a representa-
tive ¢lter is shown. C, control animals; T, tumor-bearing animals.
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anorexia observed in cancer-cachexia patients could have
some connection with impaired Kv channel expression. In-
deed, Kv3.1/Kv3.3 double knock-out mice gained less weight
than their litter mates; some began to lose weight gradually
and died. However, no references to control of food uptake
are available though surviving double mutants reached only
50^60% of the body weight of their control animals [39]. In
another study, genetically de¢cient KvL animals had problems
with learning and feeding conducts [37]. Changes in pro- and
anti-in£ammatory cytokine production have been observed in
brain during cancer cachexia [2^6] and the potential role
of these molecules in Kv channel regulation should be eval-
uated.
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